Cumberland Pharmaceuticals (CPIX) – Company Press Releases
-
Cumberland Pharmaceuticals Reports Annual 2023 Financial Results
-
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS
-
Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results
-
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS
-
NEW VIBATV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGE
-
Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023
-
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS
-
NEW PUBLICATION SUPPORTS THE USE OF CALDOLOR® IN NEWBORN PEDIATRIC PATIENTS
-
CUMBERLAND PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND FOR NEW TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
-
CALDOLOR® NOW FDA APPROVED FOR TREATMENT OF FEVER & PAIN IN INFANTS
-
Cumberland Pharmaceuticals Reports First Quarter 2023 Financial Results & Company Update
-
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2023 FINANCIAL RESULTS
-
CUMBERLAND PHARMACEUTICALS REPORTS 17% REVENUE GROWTH FOR FULL YEAR 2022
-
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2022 FINANCIAL RESULTS
-
Cumberland Pharmaceuticals Reports 41% Revenue Growth
-
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2022 FINANCIAL RESULTS
-
CUMBERLAND PHARMACEUTICALS MOVES INTO NEW HEADQUARTERS AT BROADWEST
-
Cumberland Pharmaceuticals Reports 14% Revenue Growth
-
CUMBERLAND PHARMACEUTICALS REPORTS 2.4M PATIENT DOSES DELIVERED, NO PRODUCT RECALLS, NO FDA ISSUES IN 2021
-
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2022 FINANCIAL RESULTS
-
CUMBERLAND PHARMACEUTICALS APPOINTS MARTIN BROWN JR. TO ITS BOARD OF DIRECTORS
-
Cumberland Pharmaceuticals Reports 6% Revenue Growth
-
Cumberland Pharmaceuticals Announces Key Co-Promotion Agreement with Verity Pharmaceuticals to Expand Support for Sancuso®
-
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2022 FINANCIAL RESULTS
-
TABUK AND CUMBERLAND PARTNER TO BRING INNOVATIVE ANTIBIOTIC WITH LIFE-SAVING POTENTIAL TO MIDDLE EAST
-
CUMBERLAND PHARMACEUTICALS REPORTS 2021 FINANCIAL RESULTS & COMPANY UPDATE
-
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2021 FINANCIAL RESULTS
-
CUMBERLAND PHARMACEUTICALS ACQUIRES SANCUSO® FROM KYOWA KIRIN NORTH AMERICA
-
Caldolor® Now FDA Approved For Pre-Operative Administration
-
Cumberland Pharmaceuticals Reports Third Quarter 2021 Financial Results & Company Update
-
Cumberland Pharmaceuticals To Announce Third Quarter 2021 Financial Results
-
Cumberland Pharmaceuticals Launches RediTrex® Product Line For Active Rheumatoid, Juvenile Idiopathic And Severe Psoriatic Arthritis
-
Cumberland Pharmaceuticals Reports Second Quarter 2021 Financial Results & Company Update
-
Cumberland Pharmaceuticals To Announce Second Quarter 2021 Financial Results
-
Cumberland Pharmaceuticals Reports 2.5M Patient Doses Delivered, No Product Recalls, No FDA Issues in 2020
-
Vibativ® Effectively Helps Treat Secondary Bacterial Infections In COVID-19 Patients
-
Cumberland Pharmaceuticals Names John Hamm New Chief Financial Officer
-
Cumberland Pharmaceuticals Reports First Quarter 2021 Financial Results & Company Update
-
Cumberland Pharmaceuticals To Announce First Quarter 2021 Financial Results
-
Cumberland Pharmaceuticals Reports 9% Revenue Growth In 2020
-
Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2020 Financial Results
-
Introducing RediTrex®, A New Methotrexate Delivery System
-
Cumberland Pharmaceuticals Reports Third Quarter 2020 Financial Results & Company Update
-
Cumberland Pharmaceuticals To Announce Third Quarter 2020 Financial Results
-
Newly Published Literature Supports Use Of Caldolor® For Postoperative Pain And Reduction Of Opioid Use
-
Cumberland Pharmaceuticals Reports Second Quarter 2020 Financial Results & Company Update
-
Cumberland Pharmaceuticals To Announce Second Quarter 2020 Financial Results
-
Caldolor® Demonstrates Significant Reduction Of Opioid Use In Orthopedic Trauma Patients
-
New Publication Reveals Real-World Usage of Vibativ® In Patients With Bacteremia Or Endocarditis
-
Cumberland Pharmaceuticals Reports First Quarter 2020 Financial Results & Company Update
Back to CPIX Stock Lookup